Mimae T et al. showed that SIX1 was 136-fold upregulated in microinvasion cancer cells compared to lepidic growth cancer cells in minimally invasive adenocarcinomas using a laser capture microdissection system 15, suggesting that SIX1 may be a reliable progressive biomarker in NSCLC. This evidence concerns the gene SIX1 and cancer.